Actively Recruiting
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Led by Liverpool University Hospitals NHS Foundation Trust · Updated on 2024-08-30
282
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
L
Liverpool University Hospitals NHS Foundation Trust
Lead Sponsor
K
Kidney Research United Kingdom
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating a new blood test to detect antibodies that may form after kidney transplant. These antibodies can be hard to identify because they cause no symptoms but can damage the kidney. The study compares this new test with existing antibody tests to see how well it detects antibody-related inflammation versus other types of inflammation like urinary tract infections. It also investigates whether patients over 60 years old are less likely to experience immune reactions, such as rejection, compared to younger patients. The findings could help tailor immunosuppression treatments based on patient age groups to reduce risks associated with these drugs. The study involves three main parts: a cf-DNA arm where high-risk kidney transplant patients receive a blood test measuring donor-derived cell-free DNA between 6 to 12 months post-transplant alongside standard tests; monitoring immunological events and antibody formation in patients younger and older than 60 through routine sample collection; and developing machine learning predictive models for antibody formation in unsensitized patients within one year of transplant. Blood, urine, and ultrasound tests are part of routine care and used for research without extra visits. Participants will provide samples during regular outpatient visits, including blood for the new cf-DNA test and standard monitoring tests such as donor-specific antibodies and viral PCRs. The study tracks outcomes like antibody development, infections, graft function, and patient survival over about one year. Researchers also use machine learning to identify who is most at risk for antibody formation. No extra hospital visits beyond usual care are expected, and all testing aligns with routine post-transplant monitoring schedules.
CONDITIONS
Brief Title
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients transplanted within 6-12 months or admitted for renal transplant within the first 6 months
- Patients must have capacity to provide informed consent
- Patients must have received a high-risk transplant defined as level 4 mismatch, cRF >20%, second or subsequent transplant, ABO or HLA incompatible
- Any adult patient with capacity undergoing or within 72 hours of a renal transplant
- Unsensitized patients pre-transplant for predictive model study
You will not qualify if you...
- Patients transplanted for longer than 12 months
- Patients with low risk transplants
- Patients lacking capacity to consent
- Patients transplanted longer than 2 weeks for older age immunological events and predictive model studies
- Sensitized patients for predictive model study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) during a routine outpatient appointment
Duration - Up to 1 year
Participants who have received a renal transplant are monitored through routine outpatient visits. Blood and urine samples are collected, and clinical evaluations are performed to assess immunological events and antibody formation.
Regular outpatient visits for routine post-transplant care with blood and urine tests
Duration - Single assessment at 6 to 12 months post-transplant
Participants deemed high-risk post-transplant have additional blood sampling to test donor-derived cell-free DNA (dd-cfDNA) alongside standard care tests to detect graft injury and antibody-mediated rejection.
1 visit (blood sample and ultrasound) during routine post-transplant testing
Duration - Up to 1 year following transplant
Participants continue to be observed with assessments including antibody monitoring and clinical outcomes collection to evaluate immunological events and graft function over time.
Multiple visits aligned with routine outpatient care
Trial Site Locations
Total: 1 location
1
Liverpool University Hospitals NHS Foundation Trust
Liverpool, Merseyside, United Kingdom, L7 8YE
Actively Recruiting
Research Team
G
George E Nita, MBChB MSc MRCSEd
P
Petra M Goldsmith, MBBChir PhD FRCS
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here